Light Mode
$28.95 ↑ +0.60 (+2.12%) Trading Up from the previous close of $28.35, $0.56 below the day’s high of $29.51
-20.34 (-41.77%) / 6M
Momentum, market sentiment, and recent alerts
SUPN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -36.7%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.